Who are Antipseudomonal beta-lactam antibiotic's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/antipseudomonal-beta-lactam-antibiotic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Antipseudomonal beta-lactam antibiotic — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antipseudomonal beta-lactam antibiotic (Antipseudomonal beta-lactam antibiotic) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antipseudomonal beta-lactam antibiotic. Area: Infectious Disease.

phase 3 Antipseudomonal beta-lactam antibiotic Penicillin-binding proteins (PBPs) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Antipseudomonal beta-lactam antibiotic (Antipseudomonal beta-lactam antibiotic) — Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall rupture and bacterial death, with activity against Pseudomonas aeruginosa and other gram-negative organisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Antipseudomonal beta-lactam antibiotic TARGET	Antipseudomonal beta-lactam antibiotic	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	phase 3	Antipseudomonal beta-lactam antibiotic	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antipseudomonal beta-lactam antibiotic class)

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antipseudomonal beta-lactam antibiotic — Competitive Intelligence Brief. https://druglandscape.com/ci/antipseudomonal-beta-lactam-antibiotic. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab